Serious mental illness and physical health problems: A discussion paper

International Journal of Nursing Studies

Volumn 44, Issue 3, 2007, Pages 457-466

  Robson, Debbie ^a   Gray, Richard ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Antipsychotic medication; Health behaviours; Lifestyle; Physical health; Serious mental illness

Indexed keywords

EID: 33847246338     PISSN: 00207489     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijnurstu.2006.07.013     Document Type: Note

References (90)

1. Addington J., el-Guebaly N., Campbell W., Hodgins D.C., and Addington D.L. Smoking cessation treatment for patients with schizophrenia. American Journal of Psychiatry 155 (1998) 974-976
2. Alder L.E., Olincy A., Waldo M., Harris J., Griffith J., Stevens K., Flach K., Nagamoto H., Bickford P., Leonard S., and Freedman R. Schizophrenia, sensory gating and nicotinic receptors. Schizophrenia Bulletin 24 2 (1998) 189-202
3. Allison D.B., Fontaine K.R., Heo M., Mentore J.L., Cappelleri J.C., Chamdler L.P., Wieden P.J., and Cheskin L.J. The distribution of body mass index among individuals with and without schizophrenia. Journal of Clinical Psychiatry 60 4 (1999) 215-220
4. Arrufo J., Coverdale J., Chako R., et al. Knowledge about AIDS among women psychiatric outpatients. Hospital and Community Psychiatry 41 (1990) 326-328
5. Astra Zeneca 2005. Prescribing Information. Astra Zeneca Pharmaceuticals, Wilmington, USA, retrieved 22/3/06 from http://www.astrazeneca-us.com/pi/seroquel
6. Blank M.B., Mandell D.S., Aiken L., and Hadley T.R. Co occurrence of HIV and serious mental illness among medicaid recipients. Psychiatric Services 53 7 (2002) 868-873
7. Brown S. Excess mortality of schizophrenia: a meta analysis. British Journal of Psychiatry 171 (1997) 502-508
8. Brown S., Birtwistle J., Roe L., and Thompson C. The unhealthy lifestyle of people with schizophrenia. Psychological Medicine 29 (1999) 697-701
9. Brown S., Inskipp H., and Barraclough B. Causes of excess mortality of schizophrenia. British Journal of Psychiatry 177 (2000) 212-217
10. Brugha T.S., Wing J.K., and Smith B.L. Physical Health of the long term mentally ill in the community: is there unmet need?. British Journal of Psychiatry 155 (1989) 777-781
11. Burns T., and Cohen A. Item of service payments for general practitioner care of severely mentally ill persons: does the money matter?. British Journal of General Practice 48 (1998) 1415-1416
12. Busche B., and Holt R. Prevalence of diabetes and impaired glucose tolerance in patients with schizophrenia. British Journal of Psychiatry 184 (2004) S67-S71
13. Casey D.E. Dyslipidemia and atypical antipsychotic drugs. Journal of Clinical Psychiatry 65 Suppl. 18 (2004) 27-35
14. Casey, D.E., Hanson, T.E., 2003. In: Meyer, J.M., Nasrallah, H.A., (Eds.), Medical Illness and Schizophrenia. American Psychiatric Publishing, Vancouver.
15. Cohen M.E., Dembling B., and Schorling J.B. The association between schizophrenia and cancer: a population-based mortality study. Schizophrenia Research 57 (2002) 139-146
16. Cournos F., McKinnon M.A., and Sullivan G. Schizophrenia and comorbid human Immunodeficiency Virus or Hepatitis C Virus. Journal of Clinical Psychiatry 66 Suppl. 6 (2005) 27-33
17. Coverdale J.H., and Turbott S.H. Risk behaviours for sexually transmitted infections among men with mental disorders. Psychiatric Services 51 2 (2000) 234-238
18. Dalack G.W., Healy D.J., and Meador-Woodruff J.H. Nicotine dependence in schizophrenia: clinical phenomena and laboratory findings. American Journal of Psychiatry 155 (1998) 1490-1501
19. de Leon J., Becona E., Gurpegui M., Gonzalez-Pinto A., and Diaz F.J. The association between high nicotine dependence and severe mental illness may be consistent across countries. Journal of Clinical Psychiatry 63 9 (2002) 812-816
20. Department of Health. Diabetes National Service Framework (2001), Department of Health, London
21. Department of Health. At Least 5 a Week (2004), Department of Health, London
22. Doran C.M. Prescribing Mental Health Medication. The Practitioners Guide (2003), Routledge, New York
23. Dickson R.A., and Glazer W.M. Neuroleptic-induced hyperprolactinaemia. Schizophrenia Research 35 (1999) s75-s86
24. Dixon L., Leticia P., Delahanty J., Fischer P.J., and Lehman A. The association of medical co morbidity in schizophrenia with poor physical health. Journal of Nervous and Mental Disease 187 8 (1999) 496-502
25. Dworkin R.H. Pain insensitivity in schizophrenia: neglected phenomena and some implications. Schizophrenia Bulletin 20 (1994) 235-248
26. Expert Panel on the diagnosis and classification of Diabetes Mellitus. Diagnosis and classification of Diabetes Mellitus. Diabetes Care 27 (2004) S5-S10
27. Friedlander A.H., and Marder S.R. The psychopathology, medical management and dental implications of schizophrenia. Journal of American Dental Association 133 (2002) 603-610
28. George T.P., Ziedonis D.M., Feingold A., et al. Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia. American Journal of Psychiatry 157 (2000) 1835-1842
29. George T.P., Vessichio J.C., and Tremine A. A placebo controlled trial of buproprion for smoking cessation in Schizophrenia. Biological Psychiatry 52 (2002) 53-61
30. Goff D.C., Henderson D.C., and Amico E. Cigarette smoking in schizophrenia: relationship to psychopathology and medication side effects. American Journal of Psychiatry 149 (1992) 1189-1194
31. Goff D.C., Sullivan L.M., McEvoy P., Meyer J.M., Nasrallah H.A., Daumit G.L., Lamberti S., D'Agnosino R.B., Stoup T.S., Davis S., and Lieberman J.A. A comparison of ten year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophrenia Research 80 (2005) 45-53
32. Gough S., and Peveler R. Diabetes and its prevention: pragmatic solutions for people with schizophrenia. British Journal of Psychiatry 184 Suppl. 47 (2004) s106-s111
33. Gournay K. Setting clinical standards for care in schizophrenia. Nursing Times 92 7 (1996) 36-37
34. Gray R. Medication related cardiac effects and sudden deaths among people receiving antipsychotics for schizophrenia. Mental Health and Learning Disabilities Care 4 9 (2001) 302-304
35. Gray R., Parr A.M., Plummer S., Sandford T., Ritter S., Mundt-Leach R., Goldberg D., and Gournay K. A national survey of practice nurse involvement in mental health interventions. Journal of Advanced Nursing 30 4 (1999) 901-906
36. Greening J. Physical health of patients in rehabilitation and recovery: a survey of case note records. Psychiatric Bulletin 29 (2005) 210-212
37. Halbreich U., and Kahn L.S. Hyperprolactinemia and schizophrenia: mechanisms and clinical aspects. Journal of Psychiatric Practice 9 5 (2003) 344-351
38. Halbreich U., and Palter S. Accelerated osteoporosis in psychiatric patients: possible pathophysiology processes. Schizophrenia Bulletin 22 3 (1996) 447-454
39. Halbreich U., Shen J., and Panaro V. Are chronic psychiatric patients at an increased risk for developing breast cancer?. American Journal of Psychiatry 153 (1996) 559-560
40. Harris E.C., and Barrowclough B. Excess mortality of mental disorder. British Journal of Psychiatry 173 (1998) 11-53
41. Holt R.I.G., and Peveler R.C. Association between antipsychotic drugs and diabetes. Diabetes, Obesity and Metabolism 8 (2005) 125-135
42. Holt R.I.G., Peveler R.C., and Byrne C.D. Schizophrenia, the metabolic syndrome and diabetes. Diabetic Medicine 21 (2004) 515-523
43. Hughes J.R., Hatsukami D.K., Mitchell J.E., et al. Prevalence of smoking among psychiatric outpatients. American Journal of Psychiatry 143 (1986) 993-997
44. Hummer M., and Huber J. Hyperprolactinaemia and antipsychotic therapy in schizophrenia. Current Medical Research Opinion 20 2 (2004) 189-197
45. Isaac N.E., Walker A.M., Jick H., and Gorman M. Exposure to phenothiazine drugs and risk of cataracts. Archives of Ophthalmology 109 2 (1991) 256-260
46. Jeste D., Gladsjo J., Lindmayer L., and Lacro J. Medical co morbidity in schizophrenia. Schizophrenia Bulletin 22 3 (1996) 413-430
47. Jin H., Meyer J.M., and Jeste D.V. Atypical antipsychotics and glucose dysregulation: a systematic review. Schizophrenia Research 71 (2004) 195-212
48. Kalichman S.C., Kelly J.A., Johnson J.R., and Bulto M. Factors associated with risk for HIV infection among chronic mentally ill adults. American Journal of Psychiatry 151 2 (1994) 221-227
49. Kelly C., and McCreadie R. Cigarette smoking and schizophrenia. Advances in Psychiatric Treatment 6 (2000) 327-332
50. Killion J.G., Kerr K., and Lawrence C. Myocarditis and cardiomyopathy associated with clozapine. Lancet 354 (1999) 1841-1845
51. Kinon B.J., Gilmore J.A., Lui H., and Halbreich U.M. Psychonendocrinology 28 (2003) 55-68
52. Koran D. Diabetes mellitus and schizophrenia: historical perspective. British Journal of Psychiatry 184 Suppl. 47 (2004) s64-s66
53. Lambert T.J.R., Velakoulis D., and Pantelis C. Medical co morbidity in schizophrenia. Medical Journal of Australia 178 (2003) S67-S70
54. Lawn S.J., Pols R.G., and Barber J.G. Smoking and quitting: a qualitative study with community-living psychiatric clients. Social Science & Medicine 54 (2002) 93-104
55. Lichtermann D., Ekelund J., Pukkala E., Tanskanen, and Lonnqvist J. Incidence of cancer among persons with schizophrenia and their relatives. Archives of General Psychiatry 58 6 (2001) 573-578
56. Luckstead A., Dixon L.B., and Sembly J. A focus group pilot study of tobacco smoking among psychosocial rehabilitation clients. Psychiatric Services 51 12 (2000) 1544-1548
57. Marder S.R., Essock S.M., Miller A.L., Buchanan R.W., et al. Physical health monitoring of patients with schizophrenia. American Journal of Psychiatry 161 (2004) 1334-1349
58. McCreadie R. Diet, smoking and cardiovascular risk in people with schizophrenia. British Journal of Psychiatry 183 (2003) 534-539
59. McCreadie R., Stevens H., Henderson J., Hall D., McCaul R., Filik R., Young G., Sutch G., Kanagaratnam G., Perrington S., McKendrick J., Stephenson D., and Burns T. The dental Health of people with schizophrenia. Acta Psychiatrica Scandinavica 110 (2004) 306-310
60. McNeill A. Smoking and Mental Health: A Review of the Literature (2001), Smoke Free London, ASH
61. Mortenson P.B. The incidence of cancer in schizophrenia patients. Journal of Epidemiology and Public Health 43 (1989) 43-47
62. Mortensen P.B. The occurrence of cancer in first admitted schizophrenic patients. Schizophrenia Research 12 (1994) 185-194
63. Nash M. Physical care skills: a training needs analysis of inpatient and community mental health nurses. Mental Health Practice 9 4 (2005) 20-23
64. National Institute of Clinical Excellence. Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care (2002), National Institute for Clinical Excellence, London
65. Newcomer J., Haupt D.W., Fucetola R., Melson A.K., Schweiger J.A., Cooper B.P., and Selke G. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Archives of General Psychiatry 59 (2002) 337-345
66. Newman S.C., and Bland R.C. Mortality in a cohort of patients with schizophrenia: a record linage study. Canadian Journal of Psychiatry 36 4 (1991) 239-245
67. Osby U., Correia N., Brant L., Ekbom A., and Sparen P. Mortality and causes of death in schizophrenia in Stockholm County, Sweden. Schizophrenia Research 45 (2000) 21-28
68. Paton C., Esop R., Young C., and Taylor D. Obesity, dyslipedeamias and smoking in an in patient population treated with antipsychotic drugs. Acta Psychiatrica Scandinavica 110 4 (2004) 299-305
69. Peet M. Diet, diabetes and schizophrenia: review and hypothesis. British Journal of Psychiatry 184 Suppl. 47 (2004) s102-s105
70. Phelan M., Stradins L., and Morrison S. Physical health of people with severe mental illness. British Medical Journal 322 (2001) 443-444
71. Rosenberg S., Goodman L.A., and Osher F.C. Prevalence of HIV, Hepatitis B and Hepatitis C in people with sever mental illness. American Journal of Public Health 91 (2001) 31-37
72. Ruigomez A., Rodriguez L.A.G., Dev V.J., Arellano F., and Raniwala J. Are schizophrenia or antipsychotic drugs a risk factor for cataracts?. Epidemiology 11 (2000) 620-623
73. Ryan M.C., and Thakore J.H. Physical consequences of schizophrenia and its treatment: the metabolic syndrome. Life Sciences 71 3 (2001) 239-257
74. Sewell D.D. Schizophrenia and HIV. Schizophrenia Bulletin 22 (1996) 465-473
75. Shahzad S., Suleman M.I., Shahab H., Mazour I., Kaur A., Rudzinskiy, and Lippmann. Cataract occurrence with antipsychotic drugs. Psychosomatics 43 (2002) 354-359
76. Sokal J., Messias E., Dickerson F.B., Kreyenbuhl J., Brown C.H., Goldberg R.W., and Dixon L.B. Comorbidity of medical illnesses among adults with serious mental illness who are receiving community psychiatric services. Journal of Nervous & Mental Disease 192 6 (2004) 421-427
77. Schoos R., and Cohen C.I. In: Meyer J.M., and Nasrallah H.A. (Eds). Medical Illness and Schizophrenia (2003), American Psychiatric Publishing, Vancouver
78. Thakore J.H., Mann J.N., Vlahos I., Martin A., and Reznek R. Increased visceral fat distribution in drug-naïve and drug free patients with schizophrenia. International Journal of Obesity Related Metabolic Disorders 26 (2002) 137-141
79. Taylor D., Paton C., and Kerwin R. The South London and Maudsley NHS Trust and Oxleas NHS Trust 2005-2006 Prescribing Guidelines. eighth ed (2005), Taylor & Francis, London
80. UNAIDS/WHO. AIDS Epidemic Update (2005), UNAIDS/WHO, Geneva
81. Victorian Mental Health Services. Improved Access Through Co ordinated Client Care 94/0285 (1995), Victorian Government Department of Health and community Services, Melbourne
82. Veerland B., Minsky S., Menza M., Rigassio R.D., Roemhold-Hamm B., and Stern R. A programme for managing weight gain associated with atypical antipsychotics. Psychiatric Services 54 (2003) 1155-1157
83. Weiner E., Ball M.P., Summerfelt A., Gold J., and Buchanan R.W. Effects of sustained release buproprion and supportive group therapy on cigarette consumption in patients with schizophrenia. American Journal of Psychiatry 158 (2001) 635-637
84. Werneke U., Taylor D., Sanders T.A.B., and Wessley S. Behavioural management of antipsychotic weight gain: a review. Acta Psychiatrica Scandinavica 108 (2003) 252-259
85. West R., McNeill A., and Raw M. Smoking cessation guidelines for health professionals. Thorax 55 (2000) 987-999
86. Wirshing D.A., and Meyer J.M. In: Meyer J.M., and Nasrallah H.A. (Eds). Medical Illness and Schizophrenia (2003), American Psychiatric Publishing, Vancouver
87. Wirshing D., Smith R.A., Erickson Z., Mena S.J., and Wirshing W. A wellness class for inpatients with psychotic disorders. Journal of Psychiatric Practice 12 1 (2006) 24-29
88. Wudarsky M., Nicolson R., Hamburger S.D., et al. Elevated prolactin in pediatric patients on typical and atypical antipsychotics. Journal of Child and Adolescent Psychopharmacology 9 (1999) 239-245
89. World Health Organisation. Global Strategy on Diet, Physical Activity and Health (2003), WHO, Geneva
90. World Health Organisation. Preventing Chronic Disease: a Vital Investment (2005), WHO, Geneva